Checklist for Evaluating a Cartridge-Based Molecular Diagnostic Platform in India

Introduction

India carries one of the highest tuberculosis burdens in the world, and drug-resistant TB is a growing concern. Indian laboratory directors need affordable, rapid molecular diagnostics — but evaluating a new cartridge-based platform from a Chinese manufacturer requires a systematic approach. This article is a practical guide for Indian laboratory directors evaluating the iFIND molecular diagnostics platform.

The Local Problem

India's TB programme depends on molecular diagnostics that are accurate, affordable, and serviceable locally. Cartridge-based platforms that detect TB and rifampicin resistance quickly can shorten the time to appropriate treatment. However, a platform that is not registered with the CDSCO, not serviced locally, or not documented in a language Indian staff can use cannot be deployed safely.

The Chinese Solution Scope

The iFIND platform is an automated, cartridge-based molecular diagnostics system with random-access capability. Two kits are relevant to TB:

• iFIND TBR — detects the M. tuberculosis complex and rifampicin resistance. Targets: IS6110, IS1081 / IS1087 (manufacturer documents disagree), rpoB. Manufacturer-stated LoD: 10 CFU/mL for TB, 100 CFU/mL for rifampicin. Turnaround time: 85 min in one source, 120 min in another (unresolved).
• iFIND IFQ — detects isoniazid and fluoroquinolone resistance. Targets: katG, inhA, gyrA. Manufacturer-stated LoD: 100 CFU/mL. Turnaround time: 120 min.

The system is available as S2 (2 positions), S4 (4 positions), and S8 (8 positions), with manufacturer-stated theoretical throughput of 16, 32, and 64 tests per 8 hours respectively.

Evidence Boundary

All of the parameters above are manufacturer-provided. The available evidence is limited to manufacturer brochures, technical specification sheets, and instructions for use. CDSCO registration status is not verified. No independent peer-reviewed clinical study has been confirmed. The IS1081 / IS1087 target conflict and the 85-minute versus 120-minute turnaround-time discrepancy are documented and unresolved.

Evaluation Checklist for Indian Labs

1. Regulatory status

• [ ] Confirm whether the instrument and each reagent kit are registered with the CDSCO.
• [ ] Obtain the CDSCO registration certificate numbers and verify them in the official registry.
• [ ] Check the validity period of each registration.
• [ ] Do not deploy the platform clinically until CDSCO registration is confirmed.

2. Technical specifications

• [ ] Obtain the IFU and technical specification sheet for TBR and IFQ.
• [ ] Confirm the amplification targets and resolve the IS1081 / IS1087 discrepancy with the manufacturer.
• [ ] Confirm the LoD values (10 CFU/mL TB, 100 CFU/mL rifampicin for TBR; 100 CFU/mL for IFQ).
• [ ] Confirm the turnaround time and resolve the 85-minute versus 120-minute discrepancy.
• [ ] Confirm the list of compatible specimen types (sputum, BAL, others).

3. Local validation plan

• [ ] Draft a validation protocol with acceptance criteria.
• [ ] Select a reference method (culture, CBNAAT, LPA) for comparison.
• [ ] Plan to assess accuracy, precision, LoD, cross-reactivity with non-tuberculous mycobacteria, and inhibition.
• [ ] Determine the sample size per your laboratory's internal procedures and applicable Indian regulations.

4. Service and support

• [ ] Confirm whether an authorised service centre exists in India.
• [ ] Confirm the response time for service requests and the availability of spare parts.
• [ ] Confirm warranty and post-warranty service terms.
• [ ] Confirm the consumables (cartridge) supply chain, lead times, and storage conditions.

5. Training and documentation

• [ ] Confirm training availability for Indian staff.
• [ ] Confirm documentation in English and, where needed, in Hindi or other Indian languages.
• [ ] Confirm software localisation and LIS compatibility.

6. Cost

• [ ] Calculate the cost per test (reagents plus consumables).
• [ ] Calculate annual service and maintenance cost.
• [ ] Compare with alternatives available in India.

Local Implementation Gap

Before the iFIND platform can be used clinically in India, the following must be resolved: CDSCO registration (not verified), local service network (not confirmed), Hindi documentation (not available), and local validation on Indian samples (not performed). Until these are resolved, the platform should be treated as evaluation-only.

Important Note

All iFIND parameters in this article are manufacturer-provided and not independently verified. No CDSCO registration is claimed. SinoBio Access is not a distributor and does not sell medical devices.